Cholesterol-end-modified-PEG vesicle: DDS carrier with long-term stability to encapsulate a drug model by facile preparation

被引：1

作者：

Watanabe, Shota ^{[1
]}

Asayama, Shoichiro ^{[1
]}

机构：

[1] Tokyo Metropolitan Univ, Dept Appl Chem, 1-1 Minami-Osawa, Hachioji, Tokyo 1920397, Japan

来源：

CHEMISTRY LETTERS | 2024年 / 53卷 / 10期

基金：

日本学术振兴会;

关键词：

cholesterol end-modified PEG; drug delivery system (DDS); DDS carrier; self-assemble; vesicle; POLY(ETHYLENE GLYCOL); CIRCULATION TIME; NANOPARTICLES; ETHER;

D O I：

10.1093/chemle/upae166

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Vesicles such as liposomes are widely used as drug delivery system (DDS) carriers. On the other hand, they are complicated to prepare and have stability issues. In this study, we synthesized an amphiphile, Chol-U-Et-mPEG500, containing cholesterol and poly(ethylene glycol) (PEG) as a hydrophobic and hydrophilic block, respectively. Chol-U-Et-mPEG500 spontaneously formed a vesicle with a uniform particle size of about 90 nm just by dissolving its compound in water. The vesicle encapsulated sulforhodamine B as a drug model only by mixing with its solution. Graphical Abstract

引用

页数：4

共 35 条

[1] Engineered Nanomaterials: The Challenges and Opportunities for Nanomedicines [J].

Albalawi, Fahad ;

Hussein, Mohd Zobir ;

Fakurazi, Sharida ;

Masarudin, Mas Jaffri .

INTERNATIONAL JOURNAL OF NANOMEDICINE, 2021, 16 :161-184

[2]

ANANTHAPADMANABHAN KP, 1985, LANGMUIR, V1, P352, DOI 10.1021/la00063a015

[3] Byproduct-Free Intact Modification of Insulin by Cholesterol End-Modified Poly(ethylene glycol) for in Vivo Protein Delivery [J].

Asayama, Shoichiro ;

Nagashima, Kana ;

Negishi, Yoichi ;

Kawakami, Hiroyoshi .

BIOCONJUGATE CHEMISTRY, 2018, 29 (01) :67-73

[4] Bilayer stability and impermeability of nonionic surfactant vesicles sterically stabilized by PEG-cholesterol conjugates [J].

Beugin-Deroo, S ;

Ollivon, M ;

Lesieur, S .

JOURNAL OF COLLOID AND INTERFACE SCIENCE, 1998, 202 (02) :324-333

[5] Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol) lipids [J].

Bradley, AJ ;

Devine, DV ;

Ansell, SM ;

Janzen, J ;

Brooks, DE .

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1998, 357 (02) :185-194

[6] Polymeric vesicles in biomedical applications [J].

Brinkhuis, Rene P. ;

Rutjes, Floris P. J. T. ;

van Hest, Jan C. M. .

POLYMER CHEMISTRY, 2011, 2 (07) :1449-1462

[7] A novel truncated basic fibroblast growth factor fragment-conjugated poly (ethylene glycol)-cholesterol amphiphilic polymeric drug delivery system for targeting to the FGFR-overexpressing tumor cells [J].

Cai, Lulu ;

Qiu, Neng ;

Li, Xia ;

Luo, Kaili ;

Chen, Xiang ;

Yang, Li ;

He, Gu ;

Wei, Yuquan ;

Chen, Lijuan .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2011, 408 (1-2) :173-182

[8] Preparation of long-circulating immunoliposomes using PEG-cholesterol conjugates: effect of the spacer arm between PEG and cholesterol on liposomal characteristics [J].

Carrion, C ;

Domingo, JC ;

de Madariaga, MA .

CHEMISTRY AND PHYSICS OF LIPIDS, 2001, 113 (1-2) :97-110

[9] Understanding the rod-to-tube transformation of self-assembled ascorbyl dipalmitate lipid nanoparticles stabilized with PEGylated lipids [J].

Chen, Ziqiao ;

Higashi, Kenjirou ;

Shigehisa, Yuki ;

Ueda, Keisuke ;

Yamamoto, Keiji ;

Moribe, Kunikazu .

NANOSCALE, 2023, 15 (06) :2602-2613

[10] Addressing the Cold Reality of mRNA Vaccine Stability [J].

Crommelin, Daan J. A. ;

Anchordoquy, Thomas J. ;

Volkin, David B. ;

Jiskoot, Wim ;

Mastrobattista, Enrico .

JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 110 (03) :997-1001

← 1 2 3 4 →